Bristol Myers Squibb™

2022

PHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM
Dear Prospective Fellow,

On behalf of Bristol Myers Squibb (BMS) and the Ernest Mario School of Pharmacy, we would like to thank you for your interest in the Post-Doctoral Pharmaceutical Industry Fellowship Program. The pharmaceutical industry provides many exciting and dynamic opportunities, and the same is true at BMS in particular.

BMS truly differentiates itself by combining the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company. We never give up in our search for the next innovation that could mean new hope for patients who are urgently seeking new treatment options today. Constantly pushing the boundaries of scientific excellence, our medicines help millions of people in their fight against serious diseases. Focused on addressing areas of significant unmet medical need, we have exciting development programs in areas such as oncology, hematology, immunology and cardiovascular diseases.

We recognize the importance of social responsibility and the innovative medicines we create. Our belief that “the priceless ingredient of every product is the integrity of its maker,” shines through in how we hold ourselves to the highest standard of integrity. We are not only committed to making a difference in the lives of patients, but also in the global communities where we operate.

BMS places an equal commitment to the development of the individuals who work with us. To meet our mission of helping patients prevail over serious diseases, we are committed to developing a workforce that is diverse, inclusive and representative of the communities in which we operate. We want employees to bring their authentic selves to work and to use their perspectives to contribute in a unique and meaningful way to our mission. We champion these efforts at the highest levels of our organization to ensure our people are engaged and empowered.

Over the past 25 years, we have been creating a best-in-class Fellowship program devoted to preparing unique and highly motivated individuals, like yourself, for a rewarding and successful career in our industry.

On behalf of everyone at BMS, we invite you to strongly consider joining our community of people working together to transform the lives of patients through one of the fellowships we offer. We wish you the best of luck during the recruitment process.

Sincerely,
Chris Boerner
Executive Vice President and Chief Commercialization Officer
# Table of Contents

ABOUT BRISTOL MYERS SQUIBB......................................................................................................................... 4-5

PROGRAM DESCRIPTION
- Rutgers Component........................................................................................................................................... 6-7
- Bristol Myers Squibb Component................................................................................................................. 8
- Our Innovative Pipeline......................................................................................................................................... 9
- BMS Fellowship Campus Locations............................................................................................................... 10
- Post-Doctoral Program Governance............................................................................................................. 11-12

ONE-YEAR RESIDENCY OFFERED 2022-2023 (PRINCETON PIKE)
- Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency............................................... 14

ONE-YEAR FELLOWSHIP OFFERED 2022-2023 (PRINCETON PIKE)
- US Commercial Regulatory Affairs: Advertising and Promotion................................................................. 15

TWO-YEAR FELLOWSHIPS OFFERED 2022-2024 (PRINCETON PIKE)
- Global Regulatory Strategy............................................................................................................................... 16
- Global Drug Development................................................................................................................................... 17
- US Medical Affairs: Oncology & Portfolio Strategy........................................................................................ 18
- US Cardiovascular Medical: Medical Strategy/Field Medical Sciences............................................................ 19
- Global & US Medical Affairs: Immunology....................................................................................................... 20
- Worldwide and US Oncology: Medical Communications/Field Medical......................................................... 21
- Worldwide & US Medical Strategy: Oncology.................................................................................................... 22
- WWV Scientific Content/HEOR Publications................................................................................................. 23
- Commercial Business Insights & Analytics....................................................................................................... 24
- Policy and Advocacy............................................................................................................................................ 26
- Worldwide Commercial Development: Oncology............................................................................................. 27

TWO-YEAR FELLOWSHIPS OFFERED 2022-2024 (SUMMIT EAST)
- Hematology/Oncology Medical Affairs: Medical Strategy............................................................................... 29
- WWV Health Economics and Outcomes Research - US Markets...................................................................... 30

NON-RECRUITING FELLOWSHIPS.......................................................................................................................... 31

LEADERSHIP SPOTLIGHT.................................................................................................................................... 32

RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB........................................................................ 33-34
About Bristol Myers Squibb

Our Mission
To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Our Commitment
To our patients and customers, employees, global communities, shareholders, environment and other stakeholders, we promise to act on our belief that the priceless ingredient of every product is the integrity of its maker. We operate with effective governance and high standards of ethical behavior. We seek transparency and dialogue with our stakeholders to improve our understanding of their needs. We take our commitment to economic, social and environmental sustainability seriously, and extend this expectation to our partners and suppliers.

Our Biopharma Success
At Bristol Myers Squibb, we uniquely combine the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers’ needs, giving maximum priority to accelerating pipeline development, delivering sales growth, and continuing to manage costs. In recent years, we have outperformed most mega pharma companies, diversified companies, and pure biotech companies, having delivered 1.4 new medicines to patients since 2002. We are a BioPharma leader with a commitment to patients with serious disease, focused on finding innovative medicines to address unmet medical needs. Having transformed Bristol Myers Squibb into a benchmark BioPharma company, we now stand on the frontier of new possibilities with a commitment to making a meaningful difference in the lives of our patients. Continuous innovation is critical to our BioPharma strategy and is enhanced by our diverse workforce and inclusive culture. Over the years, Bristol Myers Squibb and its employees have received numerous distinguished awards and recognitions, including being named one of the 50 Smartest Companies in 2015, as a leader in Immuno-oncology. Furthermore, we have the honor of continuing a legacy as one of the 100 Best Corporate Citizens, maintaining a perfect score on the Corporate Equality Index, and having been recently named one of the World’s Most Admired Companies.
Our Research And Development Strategy

At Bristol Myers Squibb, we are on the leading edge of science and technology to discover and develop new medicines. We invest significantly in Research and Development (R&D) - with an R&D organization considered among the most productive in the industry. Over the past decade, we have helped bring to market innovative medicines for therapeutic areas including cancer, HIV/AIDS, hepatitis B, rheumatoid arthritis, solid organ transplant rejection, cardiovascular disease and hepatitis C. Moving into the future, our strategic focus remains on leveraging our legacy in discovery to expand the frontiers of biomedical research and continue strengthening our innovative pipeline. Behind these innovative medicines are our extraordinary teams of people. Our future depends on our employees, and we are dedicated to their continuous development and long-term growth within our organizational structure. Each compound in development is backed by high performing, multidisciplinary teams of people committed to helping our patients prevail over serious diseases. Drug development is time consuming, expensive, and risky with an average of only one of every 10,000 compounds discovered by biopharmaceutical industry researchers moving on to become an approved medicine. However, to the people of R&D, that one success makes it all worthwhile. We are energized by our Mission to innovate medicine and measure our success by the difference we make in the lives of patients.
Rutgers Pharmaceutical Industry Fellowship Program
Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey

PROGRAM HISTORY

In 1984, at Rutgers, The State University of New Jersey, the Ernest Mario School of Pharmacy and two pharmaceutical companies began a collaborative pilot program to evaluate the potential contributions of clinically-trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program grew significantly and expanded to include 21 companies within the pharmaceutical and biopharmaceutical industry and approximately 300 Fellows.

In 2002, Dr. Ernest Mario generously provided an endowment to establish the Institute for Pharmaceutical Industry Fellowships to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

• provide leadership and administrative support;
• promote quality, communication, and scholarly activity; and
• arrange specialized fellowship training opportunities within the pharmaceutical and biopharmaceutical industry.

In 2018, our Program expanded to offer interdisciplinary Fellows’ training by adding select physician fellowship opportunities to our well-established program.

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Professor II of the Ernest Mario School of Pharmacy, Dr. Carolyn Seyss, the Director for the Institute for Pharmaceutical Industry Fellowships, and Dr. Michael Toscani as Director Emeritus.

More than 1,300 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow’s functional area(s). Our goal is to provide the environment for Fellows to build the foundations for their careers as future leaders in the industry.

PROFESSIONAL DEVELOPMENT SERIES

All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the partner companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows’ leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers. PDDs also provide general knowledge about various aspects of drug development/commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.
The Fellows can learn from each other through individual and group presentations and debates on topics and issues related to the pharmaceutical and biopharmaceutical industry. The dynamic forum of PDD provides an opportunity for open discussion and debate among fellows, Rutgers faculty, and company Preceptors. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success; professional writing, presentations, meeting facilitation, negotiating, influencing, networking, and conflict resolution skills; giving and receiving feedback; and business and dining etiquette). Other PDD guest speakers include senior industry executives, patient advocacy groups, and successful RPIF Program alumni who share their insights and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.

KEY PROGRAM FEATURES

The Rutgers Pharmaceutical Industry Fellowship Program **FOSTERs** the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders through the following key program features:

**F**amily of Leading Companies – Partners include several of the top global pharmaceutical and biopharmaceutical companies.

**O**utstanding Alumni Track Record – Over 1,300 alumni hold prominent positions at many leading companies.

**S**trong Network — Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and faculty.

**T**rusted and Proven Since 1984—the Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry for pharmacists as future leaders.

**E**nhanced Career Development – Breadth of experiences informs career path choices and increasingly challenging assignments build depth of experience, enhancing the potential for accelerated career paths.

**R**igorous Academic Component – Rutgers affiliation provides academic and professional development opportunities.

Rutgers, The State University of New Jersey, with over 71,000 students in its three campuses, is one of the major state university systems in the United States. The New Jersey College of Pharmacy was founded in 1892 and was incorporated into the University in 1927. The Ernest Mario School of Pharmacy is part of Rutgers Biomedical and Health Sciences, the only state school of pharmacy in New Jersey, with approximately 1,350 students in its Doctor of Pharmacy degree program. The Rutgers Ernest Mario School of Pharmacy is located on the University’s main science and technology campus in Piscataway, New Jersey. Because of its relationship with and, for most, close proximity to the nation’s leading pharmaceutical and biopharmaceutical companies, the Ernest Mario School of Pharmacy and the RPIF Program are uniquely capable of providing fellows with advanced training in the pharmaceutical and biopharmaceutical industry.
The Fellows will become an integral part of their respective teams and will be trained to manage a broad range of responsibilities, similar to those managed by current team members. This Fellowship program will necessitate interaction and teamwork with departments in all aspects of the corporation, such as Global Pharmacovigilance and Labeling, Sales, Medical Affairs, Marketing, Regulatory Services, Legal, Clinical Trials, Post-Marketing Clinical Research, and Health Care Channel Management. While at Bristol Myers Squibb, the Fellows will participate in various teambuilding activities and attend leadership development lectures with senior management. Key Fellowship activities within Bristol Myers Squibb include:

**MENTORSHIP PROGRAM**

Participate in a mentorship program with senior management and Fellowship alumni to discuss career development, networking, organization structure, market/industry knowledge, etc.

**LUNCH AND LEARN SERIES**

Attend lunch and learn series with executive sponsors and senior management to have interactive discussions.

**BRISTOL MYERS SQUIBB FELLOWSHIP COMMITTEES**

Lead and take part in the various Fellowship committees such as: Co-Chief Fellows, Recruitment, Community Development, Professional Development, Alumni, and Scholarship committee.
Bristol Myers Squibb focuses on discovering and developing innovative medicines that address serious diseases in areas of significant unmet medical need. We concentrate our research efforts in the following core therapeutic areas: Oncology, Hematology, Immunology, Cardiovascular, and Fibrosis.

### BRISTOL MYERS SQUIBB QUICK FACTS

- **Global Revenue of $42.5 billion in 2020**
- **R&D investment of $11.1 billion in 2020**
- **Key Product Sales in 2020:**
  - REVLIMID®, $12.1 billion
  - ELIQUIS®, $9.2 billion
  - OPDIVO®, $7.0 billion
  - ORENCIA®, $3.2 billion
  - POMALYST®, $3.1 billion
  - SPRYCEL®, $2.1 billion
  - YERVOY®, $1.7 billion
  - ABRAXANE®, $1.2 billion

### MARKETED PRODUCT DEVELOPMENT

<table>
<thead>
<tr>
<th>Category</th>
<th>MARKETED PRODUCT DEVELOPMENT</th>
<th>PHASE II/III DEVELOPMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oncology</strong></td>
<td>OPDIVO® (nivolumab)</td>
<td>Relatlimab</td>
</tr>
<tr>
<td></td>
<td>YERVOY® (ipilimumab)</td>
<td>Anti-CTLA4 Probody</td>
</tr>
<tr>
<td></td>
<td>OPDIVO® (nivolumab) + YERVOY®(ipilimumab)</td>
<td>Anti-CTLA4 NF</td>
</tr>
<tr>
<td></td>
<td>ABRAXANE® (paclitaxel protein bound)</td>
<td>Bempegaldesleukin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CCR2/5 Dual Antagonist</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LSD1 Inhibitor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BET Inhibitor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anti-TIGIT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anti-Fucosyl GM1</td>
</tr>
<tr>
<td><strong>Hematology</strong></td>
<td>REVLIMID® (lenalidomide)</td>
<td>Iberdomide</td>
</tr>
<tr>
<td></td>
<td>POMALYST® (pomalidomide)</td>
<td>BET Inhibitor</td>
</tr>
<tr>
<td></td>
<td>SPRYCEL® (dasatinib)</td>
<td>A/I CELMoD</td>
</tr>
<tr>
<td></td>
<td>EMPLLICTI® (elotuzumab)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>REBLOZYL® (luspatercept-aamt)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>INREBIC® (fedratinib)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ONUREG® (azacitidine)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ABECMA® (ide-cel)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BREVANZI® (liso-cel)</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td>ELIQUIS® (apixaban)</td>
<td>Mavacamten</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Milvekian</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Danicantiv</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FA-Relaxin</td>
</tr>
<tr>
<td><strong>Fibrosis</strong></td>
<td></td>
<td>HSP47</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pegbelfermin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JNK Inhibitor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LPA1 Antagonist</td>
</tr>
<tr>
<td><strong>Immunology</strong></td>
<td>ZEPOSIA® (ozanimod)</td>
<td>Deucravacitinib</td>
</tr>
<tr>
<td></td>
<td>ORENCIA® (abatacept)</td>
<td>Cendakimab</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Branebrutinib</td>
</tr>
</tbody>
</table>

1 Marketed Product Development compounds have been approved in at least one major market and are among approved medicines that are under further study to determine the safety and efficacy of potential additional indications and formulations. All information on this page has been pulled from the BMS 2020 Annual Report. Pipeline and Product information on this page is current as of July 1, 2020. This brochure is not intended to promote use of any Bristol Myers Squibb medicines. For more information about these and other company products, please visit Bristol Myers Squibb at [www.bms.com](http://www.bms.com).
BMS Fellowship Campus Locations

**Princeton Pike (PPK)**
Lawrenceville, NJ
(Main Campus)

**Summit East (SME)**
Summit, NJ
Post-Doctoral Program Governance

Executive Steering Committee

Melissa Harris, PharmD
Senior Vice President, Early Development Program Leadership
PPK

Samantha Gothelf, PharmD
Vice President, US Medical Oncology
PPK

Steering Committee Leads

Priya Darouian, PharmD
Director, Medical Capabilities
PPK

Carol Davis-Shiloh, PharmD
Head, US Field Medical Oncology
PPK

Thomas Lehman, PharmD
Director, TYK2i Rheumatology WW Medical
PPK

Steering Committee Members

Cathy Merrill, PharmD
Director, Early Transition Assets/Rela WW Scientific Publications
PPK

Laura Williams, PharmD
Medical Scientist, US Medical Oncology, Pan Tumor
PPK

Ijeoma Nwosu, PharmD
Associate Director Medical Scientist, US Medical Oncology GI
PPK

Jully Kim, PharmD
Director, Medical Promotional Review Lead, Hematology SME

Matt Lupo, MCIS
Director, US Commercial Regulatory Affairs, Oncology
PPK

Kevin Snyder, PharmD
Early Career Programs, Global Talent Acquisition, D&I
PPK

Kim Tran, PharmD
Executive Director, US Field Medical Hematology
PPK

Victoria Berger, PharmD
Clinical Scientist
PPK

Peter Fendt, PharmD
Associate Director, Customer & Market Insights, Hematology/CAR-T SME
Second-Year Co-Chief Fellows

Becky Fritz, PharmD
Worldwide & US Medical Strategy: Oncology (PPK)

Gabriela Sikorska, PharmD
Global & US Medical Affairs: Immunology (PPK)

Raena Rhone, PharmD
US Medical Strategy - Immunology (PPK)
2022

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM

Princeton Pike (PPK)
Lawrenceville, NJ
The Bristol Myers Squibb Foundation’s (BMSF) approach to addressing health inequities is to strengthen healthcare worker capacity, integrate medical care and community-based supportive services, and mobilize communities in the fight against diseases. This 12-month residency is offered in conjunction with Rutgers Institute for Pharmaceutical Industry Fellowships Program of Ernest Mario School of Pharmacy (EMSOP) and BMSF. As adjunct faculty at the EMSOP, there will be opportunities for the Resident to enhance his/her experience by collaborating with faculty through scholarship, publication, teaching and maintenance of clinical skills. The PharmD Resident will spend approximately six months in southern Africa as part of the BMSF team with the Global Cancer Disparities-Africa program to help build capacity and provide training to partner organizations. Activities may include:

- Training of pharmacy and other healthcare professionals in disease state management and pharmacotherapy
- Developing protocols and proposals incorporating the management of cancer from existing HIV/AIDS platforms
- Helping countries develop surveillance and registries to collect data and treatment recommendations especially as it relates to lung cancer
- Project implementation and management on field sites

The Resident will then complete the remainder of the program in Lawrence Township, New Jersey, working with the US Health Disparities in Cardiovascular and Immunologic Diseases and other BMSF initiatives that address health inequities in the United States. Activities may include:

- Researching issues for the development of grant program strategies
- Provide expert review and technical assistance for pharmacy related issues
- Connecting project goals with policy and advocacy advancement
- Reviewing grantee reports and learning responsibilities as a grant maker

In addition to the aforementioned responsibilities, there are opportunities to gain experiences within other BMSF projects including the Global Cancer Disparities - US/China/Brazil and our Diversity in Clinical Trials Career Development Program.

APPLICATION REQUIREMENTS: Applicants can pre-schedule an interview at the virtual ASHP Midyear Clinical Meeting through PPS. Requirements include: PharmD from an ACPE-accredited institution, Completion of a PGY-1 residency or equivalent experience is strongly preferred, Curriculum vitae, Three letters of recommendation, Letter of intent addressing your interest in global/public health and long term plans, Candidates must be willing and able to relocate to southern Africa for 6 months

PRECEPTORS:

- **John Damonti**  
  Vice President, Corporate Philanthropy, Bristol Myers Squibb Foundation (US)

- **Phangisile Mtshali**  
  Director, Bristol Myers Squibb Foundation (South Africa)

- **Priscilla Ko, PharmD**  
  Director, Bristol Myers Squibb Foundation (US)
US Commercial Regulatory Affairs: Advertising and Promotion

The US Commercial Regulatory Affairs group at Bristol Myers Squibb provides strategic regulatory guidance within the company on the Food and Drug Administration (FDA) advertising and promotion regulations to support good business practices. The regulatory advice is provided to the marketing organization to ensure the highest level of ethics and integrity in the promotion of Bristol Myers Squibb products. The group collaborates with a variety of functions including Marketing, Medical Affairs, Legal, Global Labeling, Managed Markets, Global Regulatory, Safety, and Biometrics. The Fellow will be assigned to a primary therapeutic area. Key activities and learnings will include:

• Gaining an understanding of and ensuring consistency between key federal regulations and Bristol Myers Squibb policies
• Analyzing the impact of FDA Office of Prescription Drug Promotion (OPDP) enforcement actions and assessing the regulatory implication to commercial activities
• Assisting in the regulatory review of proposed promotional materials and programs created by Marketing, Sales, or Corporate Affairs and submissions to OPDP
• Collaborating with matrix team members to advise on the development of marketing campaigns that meet regulatory requirements as well as commercial objectives

PRECEPTORS:

• Divisha Dixit, PharmD, MBA
  Associate Director, US Commercial Regulatory Affairs

• Christine Alonso, PharmD
  Director, US Commercial Regulatory Affairs
This two-year Fellowship provides the opportunity to establish a broad understanding of Global Regulatory Strategy and its role in the drug development process. The Fellow will obtain direct experience and exposure to products at various stages of development and will learn important considerations for working with key regulatory agencies such as FDA and EMA. Optional rotation(s) in Precision Medicine, Commercial Regulatory Affairs, Global Pharmacovigilance & Epidemiology, Global Labeling, or Chemistry Manufacturing & Controls (CMC) will allow additional experience based on fellow interest and opportunities. During this program, the fellow will:

- Participate in the development of global regulatory strategies supporting development, approval, and maintenance of drugs and biologics
- Contribute to identification and assessment of regulatory risks and their mitigation
- Participate in planning and preparing Health Authority (HA) interactions and assessing impact of HA feedback on an asset’s development plan
- Draft submission documents, including for INDs, NDA/BLAs, and expedited regulatory designation requests
- Manage responses to Health Authority queries
- Work with matrix team members (R&D and Non-R&D) to identify solutions that meet regulatory requirements as well as commercial objectives
- Work with Global Regulatory Policy team on reviewing special topics

PRECEPTORS:

- **Robert Kalesnik-Orszulak, PharmD**
  Director, Global Regulatory Sciences and Policy, Oncology

- **Vrunda Patel, PharmD**
  Associate Director, Global Regulatory Strategy and Policy, Immunoscience, Neuroscience, and Fibrosis

- **Sagar Shah, PharmD**
  Director, Innovation Lead, Global Regulatory Science and Policy
The Global Drug Development (GDD) organization is responsible for developing compounds for the treatment of various diseases worldwide. Fellows within GDD function as Associate Clinical Scientists (CS) and focus on the science and strategy of drug development. The fellows will learn various aspects of global clinical studies (Phases I-III) including study initiation, maintenance, and closure activities.

GLOBAL DRUG DEVELOPMENT FELLOWSHIP OBJECTIVES:

• Understand the key foundations of clinical trial development and how they relate to the overall drug development process (i.e. study design, selecting study endpoints, randomization/stratification, control, blinding, selection of population, and study assessments).

• Become a proficient CS and effective cross-functional study team contributor throughout the clinical trial process by learning to develop study protocols, informed consent documents, patient narratives, clinical study reports (CSR), Investigator Brochures (IB), Investigational New Drug (IND) safety updates, Development Safety Update Report (DSUR), case report forms (CRFs) and other regulatory submission documents.

• Work closely with the CS’s, CTP’s (Clinical Trial Physician) and study team in making study-specific recommendations, providing clinical research expertise, presenting protocol specific topics, responding to health authority requests, and supporting the team at various therapeutic area conferences.

• Support the study team in comprehensive clinical data review and analysis via available data review tools such as patient profiles, data review reports and data listings.

• Partner with Clinical Operations, Data Management, Statistics, Drug Safety, Regulatory, Clinical Pharmacology, Medical Writing and Marketing team to support the scientific aspects of clinical development.

The Global Drug Development Fellowship is a 2-year program primarily focused on developing new therapies in oncology, where there is a large unmet need. Bristol Myers Squibb is at the forefront of cancer research with an extensive and quickly developing pipeline. This fellowship opportunity will allow the fellows to work on novel and innovative therapies to transform the cancer treatment landscape.

Solid Tumor Oncology GDD: Recruiting 1 fellow (PPK)
Cellular Therapy GDD: Recruiting 1 fellow (SME)
Cardiovascular GDD: Not recruiting (PPK)

PRECEPTORS:

• Kristen Letrent, PharmD, BCPS
  Clinical Scientist Program Lead, Early Assets

• Joe DeStefano
  Clinical Scientist, Cell Therapy
The US Medical Affairs Oncology & Portfolio Strategy position is a two-year fellowship that ensures an integrated approach in aligning pan tumor efforts throughout the medical organization. The fellow will be able to aid the US Medical team in developing medical strategies for our marketed products as well as the assets in our pipeline, execute effective launches, and ensure the safe and appropriate use of our medicines by healthcare providers and patients. This fellowship will provide rotational experiences in three key teams within the US Medical organization: Independent Medical Education (IME) for 6 months, Pan Tumor Medical Strategy for 1 year, and Cross Portfolio Planning & Operations for 6 months.

During this program, the fellow will:

- Engage in medical strategy tactics, including thought leader interactions, advisory board discussions, gathering field therapeutic area insights, and aligning with oncology medical partners on safety/patient management, dosing, and other pan tumor topics
- Lead the strategic communication, collaboration, and awareness of pan tumor efforts while partnering on execution with functional teams including US and Worldwide Medical, Clinical Development, Commercial, Publications, Medical Information, and Field Medical
- Participate in the execution of pan tumor related deliverables including proactive healthcare provider and patient management resources, medical proactive/reactive decks, and training materials for cross-matrix colleagues
- Support high quality, innovative medical education. Create and lead the IME request for education (RFE) process for designated therapeutic areas of focus (strategy development), perform medical review and analysis of IME grant proposals, provide recommendations, and lead IME Review Committee meetings (tactical follow through on strategy)
- Analyze outcomes data from BMS-supported medical education activities, communicate to the medical matrix teams for designated therapeutic areas of focus, and attend and audit continuing medical education programs supported by BMS
- Develop an understanding of the National Cancer Institute (NCI) National Clinical Trials Network and their important collaborative research with BMS
- Participate in US Medical process improvements and initiatives

**PRECEPTORS:**

- **Nabomita Thomas, PharmD, RPh**
  Director, US Medical Oncology, Pan Tumor
- **Maria Deutsch, MS, PharmD, RPh**
  Director, Medical Education, US Oncology
- **Lynn Eagle, PharmD, MS**
  Director, US Medical Cross Portfolio Strategic Planning & Operations
- **Linda Fischer, MS**
  Director, US Medical Cross Portfolio Strategic Planning & Operations
This two-year Fellowship provides a unique opportunity to develop experiences in strategic inhouse medical affairs and field medical settings. The Fellow will acquire cardiovascular disease state knowledge and master the BMS cardiovascular product portfolio along with understanding of the relevant treatment landscapes. In addition, the Fellow will work on high priority projects and initiatives aligned with the Medical Plan to support impactful HCP interactions. The Fellow will develop leadership and communication skills through collaboration across the US Medical matrix teams and other key partners. Key activities and learnings will include:

**MEDICAL STRATEGY**
- Participate in the US Medical matrix team to support strategic planning based on the unmet medical needs from the perspectives of patients, providers, and payers
- Support the execution of the Medical Strategy tactical plan by working across matrix teams (Marketing, Field Medical, Independent Medical Education, Advocacy, Clinical Development, Legal and Regulatory) as well as with alliance partners
- Collaborate with cross-functional medical team members to deliver on key medical initiatives, including advisory boards, proactive messaging, reactive medical communication, and publication strategy
- Support development of medical training materials for sales representatives and deliver medical presentations at sales training sessions
- Lead the execution of National and International Congress planning activities as part of the CV Medical Plan

**FIELD MEDICAL SCIENCES**
- Engage thought leaders in scientific discussions during field-based activities with CV MSLs
- Assess/identify gaps in MSL resources and collaborate with medical strategy on the development of MSL scientific resources and trainings
- Collaborate with the Field Medical Leadership Team to support development and implementation of field medical priorities
- Contribute to scientific congress Field Medical initiatives

**PRECEPTORS:**
- **Lisa Rosenblatt, MD, MPH**
  Director, Cardiovascular US Medical
- **Carmelo Alonso, PharmD**
  Field Medical and Communications Specialist, Cardiovascular
Global & US Medical Affairs: Immunology

This two-year Fellowship provides a unique opportunity to work in two of the most exciting and competitive areas of immunology research and pharmaceutical development today: Rheumatology and Dermatology. Individuals participating in this fellowship will gain a broad understanding of Medical Affairs through both participatory and leadership experiences from the perspective of both the US and Worldwide Medical Strategy Teams. During the Fellowship, the fellow is expected to experience several important market events including a product launch in dermatology and several phase 2/phase 3 study read outs. Graduates of this fellowship have gone on to lead successful careers in various aspects of Medical Affairs including Medical Strategy, Scientific Communications, Clinical Development, Medical Science Liaison, Medical Information, and Independent Medical Education.

US MEDICAL STRATEGY – DERMATOLOGY & RHEUMATOLOGY

- Participate in strategic planning with the US Medical Matrix Team based on unmet medical needs from the perspectives of patients, providers, and payers
- Lead medical projects in partnership with the broader medical matrix team members (Field Medical, Medical Information, Independent Medical Education, Sales, Marketing, Outcomes Research, Promotion Integrity, Legal, and Global Pharmacovigilance & Epidemiology)
- Lead and participate in key aspects of medical affairs including data generation, content development, training, and insight identification including advisory boards and Medical Science Liaison interactions
- Conduct medical review of promotional and non-promotional materials in collaboration with Legal, Regulatory, and Marketing teams

WORLDWIDE MEDICAL STRATEGY – DERMATOLOGY & RHEUMATOLOGY

- Lead development and execution of the Global Medical Plan in partnership with key international market teams (eg, US, EU, Asia-Pacific), Clinical Development, & Commercial
- Prepare for and execute a commercial launch and several Phase 2/3 data releases for deucravacitinib (a selective TYK2 inhibitor) in Rheumatology and Dermatology
- Engage International Key Opinion Leaders via advisory boards, steering committees, MSLs, and international conferences to inform and elevate BMS strategy
- Identify educational needs among Rheumatologists and Dermatologists and execute plans to fulfill them; eg, disease education, pathway materials, conference symposia, review articles
- Develop integrated data generation plans and review/approve investigator sponsored research proposals to inform appropriate use of BMS medicines and fulfill unmet medical needs

PRECEPTORS:
- **Keith Wittstock, PharmD, MBA**
  Senior Manager, Immunology US Medical Strategy
- **Thomas Lehman, PharmD**
  Director, TYK2i Rheumatology WW Medical Strategy
Worldwide and US Oncology: Medical Communications/Field Medical

This two-year fellowship provides an opportunity to develop an understanding of the functional areas of Medical Communications and Field Medical. Fellows will be afforded the opportunity to build a strong foundation from their first year experiences in medical communications, as well as through early exposure to field interactions, that can be leveraged as they transition into a field-based role during the second year of the fellowship. Throughout the course of this fellowship, individuals will not only acquire disease state knowledge, but also master clinical data regarding Bristol Myers Squibb and competitor oncology products. Fellows will collaborate within a cross-functional matrix (e.g. Legal/Regulatory, Marketing, Medical, and R&D) through leading fellow-driven projects with demonstrable business impact.

WW AND US MEDICAL COMMUNICATIONS

• Function as a Worldwide Medical Communications Specialist to enable the healthcare community to advance the science, accelerate access, shape medical practice, and drive appropriate adoption of BMS medicines
• Act as a primary point of contact and strategic partner to ensure scientific content meets the worldwide and market needs and addresses any educational gaps
• Partner closely with the medical information contact center in responding to unsolicited requests from health care providers, payers, and patients
• Collect market-level insights for bidirectional knowledge sharing, as well as to create and deliver content focused on education to enable access within market
• Collaborate across Worldwide Scientific Content, Market Capabilities, Field Medical, and Worldwide Marketing teams to execute communication strategies

US FIELD MEDICAL ONCOLOGY

• Frequent field interaction opportunities with MSLs to obtain experience in the engagement of oncology thought leaders and other key members of the oncology healthcare team
• Play a critical role in the collection and analysis of insights, Medical Account Planning, and tumor specific training to gain an understanding of the market and therapeutic landscape
• Work directly on headquarter-based field medical projects, and attend key Bristol Myers Squibb meetings (i.e. National Oncology Meetings, Medical Congresses, Continuing Medical Education, Medical Matrix collaboration, and MSL training)
• Participate in weekly virtual Field Medical meetings (regional calls, journal clubs, and national meetings)
• Demonstrate mentorship as co-preceptor for APPE student rotations
• Analyze key field metrics and understand business impact

PRECEPTORS:

• Avani Patel, PharmD
  Associate Director, Oncology Field Medical Strategy

• Alison Quinn, PharmD
  Director, US Field Medical Oncology Training

• Zhuting Li, PhD
  Associate Director, WW Scientific Content and US Market Capabilities

• Amber M. Griffies, PharmD
  Associate Director, WW Scientific Content and US Market Capabilities
Medical Strategy is where scientific and clinical knowledge meet strategic application. This two-year Fellowship provides a unique opportunity to support the development and execution of Worldwide and US Oncology Medical Strategy and other medical activities. During the first year in Worldwide Medical, the Fellow will focus on developing the global strategy for new indications in a wide array of tumor types through collaborative efforts with BMS regional offices around the world. During the second year in US Medical, the Fellow will be on the Franchise Medical team where the focus will be on developing and executing the US strategy for the successful launch and continued support of a wide range of indications and therapeutic areas. The Fellow will gain exposure to various stakeholders and develop leadership skills by supporting and leading medical initiatives in collaboration with the Worldwide and US cross functional matrix teams (i.e., Field Medical, Medical Publications, Health Economics & Outcomes Research, Clinical Research, Clinical Operations, Regulatory, Marketing, Competitive Intelligence, and Access).

**WORLDWIDE MEDICAL STRATEGY**

- Gain experience in the development of a strategically-aligned Global Medical Plan based upon unmet medical need by collaborating with a cross functional, multi-regional (i.e., US, EU, Asia-Pacific) Worldwide Medical matrix team
- Engage with external Thought Leaders in an effort to exchange and gather scientific and clinical knowledge through investigator meetings, advisory boards, Thought Leader Engagements (TLEs), publication planning, and congresses
- Lead the execution of medical deliverables that are closely aligned with the strategic Global Medical Plan, including National and International Congress planning for activities such as advisory boards, symposia, and TLEs
- Collaborate with BMS country-specific medical colleagues to collect field insights that will support strategic planning and tactical execution
- Actively participate in the review and approval process of Investigator Sponsored Research proposals that are aligned with the data generation plan detailed in the Global Medical Plan

**US FRANCISE MEDICAL**

- Facilitate development of US portfolio franchise execution strategies and tactics through Medical and Marketing cross-functional team collaboration with experience available across Oncology, Immunology and Cardiovascular therapeutic areas
- Actively participate in development and execution of brand franchise tactics and optimization of US Franchise Medical capabilities including launch readiness plans, medical conference activities, advisory board planning and execution, Thought Leader identification and engagements, internal medical training and external education
- Engage with US Thought Leaders in scientific exchange via advisory boards, TLEs, development of educational materials, and congresses

**PRECEPTORS:**

- **Yacia Bennai, MD**  
  Vice President, Tumor Strategy & Opdivo, Worldwide Medical Oncology
- **Jessica Sheer, PharmD, MBA, CCRA**  
  Director, Franchise Medical Services, US Medical
- **Brielle Carramusca, PharmD**  
  Associate Director, Franchise Medical Services, US Medical
WW Scientific Content/HEOR Publications

This fellowship provides an opportunity to work with and learn from the Medical Capabilities organization, while communicating key clinical and economic data to inform healthcare decision-making. Over the course of two years, fellows will gain thorough experience in content creation as well as the planning and execution of important scientific communication and publication deliverables. This position will provide insights into the role of health economic and outcomes research (HEOR) in demonstrating the value of pharmaceuticals, while cultivating a knowledge of the broader organization through cross functional collaboration with various stakeholders (e.g., HEOR, Access, Medical Strategy, medical field teams, and Legal). Key activities and learnings will include:

**WW SCIENTIFIC CONTENT & US MARKET CAPABILITIES**

- Understand the information needs of healthcare professionals, US payers, and access influencers that can inform reimbursement policies, formulary decisions, and guideline recommendations for BMS products
- Collaborate with HEOR, Medical Strategy, and medical field teams to ensure scientific content is developed with a high degree of medical integrity, accuracy, and clinical and payer relevance
- Lead content creation of medical communication deliverables involving clinical studies, economic analyses, and real-world data of BMS products. Deliverables include AMCP dossier, Medicaid submissions, submissions to guideline bodies, slide decks for medical field teams, and responses to medical information inquiries

**HEOR PUBLICATIONS**

- Gain experience, through collaboration with WW and US HEOR, WW and US Medical Strategy, and other stakeholders, in developing strategic HEOR publication plans for BMS products
- In collaboration with HEOR, external authors, and appropriate internal stakeholders, develop publications adhering to BMS publication standards including abstracts, congress presentations, and manuscripts focused on the clinical and economic value of BMS products, disease burden, or unmet needs
- Lead the execution of publication plans and develop skills for managing stakeholders, both external and internal, in multiple functional areas to ensure strategic alignment of the publication plans

**PRECEPTORS:**

- **Marianne Brillantes, PharmD**
  WW Scientific Content & US Market Capabilities, Sr. Manager
- **Noble Thadathil, PharmD**
  WW Scientific Content & US Market Capabilities, Sr. Manager
- **Jigish Bhavsar, PharmD**
  WW HEOR Publications, Associate Director
- **David S. Berger, PhD**
  WW HEOR Publications, Director

Ornesha Watson, PharmD, MS  
Second-Year Fellow  
University of Saint Joseph  
School of Pharmacy

Austin Bock, PharmD  
First-Year Fellow  
Fairleigh Dickinson University  
School of Pharmacy and Health Sciences

Ornesha Watson, PharmD, MS  
Second-Year Fellow  
University of Saint Joseph  
School of Pharmacy

Austin Bock, PharmD  
First-Year Fellow  
Fairleigh Dickinson University  
School of Pharmacy and Health Sciences
At BMS, the Commercial Business Insights & Analytics (BI&A) division fuels bold decisions to create a competitive advantage and accelerate growth. This joint two-year fellowship is a unique opportunity for a Fellow to identify insights and work with others to translate these findings into actionable recommendations for senior management. The fellow will lead key projects on cross-functional teams with individuals from Marketing, Market Research, Forecasting, Competitive Intelligence, Medical Affairs, Business Development and R&D Clinical Development.

The Fellow will spend the first year in Competitive Intelligence and the second year in Market Research. While on both teams, the Fellow will synthesize data from both primary and secondary sources to develop actionable recommendations for business stakeholders. These rotational opportunities will allow the Fellow to help provide strategic insights and understand procedures within the BI&A organization. Year 1 with Competitive Intelligence will be at PPK campus and Year 2 with Market Research will be at SME campus.

**COMPETITIVE INTELLIGENCE**

- Assess the competitive environment, competitors’ assets, and emerging scientific data to inform clinical, regulatory, and commercial strategies
- Engage in monitoring and analysis of pharmaceutical industry and market trends.
- Support competitive intelligence projects that address key business questions at the brand level
- Develop and implement enterprise-level initiatives to improve and enhance competitive intelligence capabilities

**MARKET RESEARCH**

- Work closely with cross-functional teams (Marketing, Medical, Sales, Access) to understand business needs and deliver actionable insights and recommendations across different markets and disease states
- Design and execute research methodologies, working together with internal team members and outside vendors to customize research plans
- Manage primary research projects to deliver creative customer and market-based input on strategic and tactical business issues

The Fellow will develop valuable skills and experiences in identifying and prioritizing business opportunities and gaps. The Fellow will also develop transferable skills including project management, vendor management, and enhance presentation skills

**PRECEPTORS:**

- **Wilfredo Ortiz, PhD**
  Associate Director, Competitive Intelligence
- **Jeet Uppal**
  Senior Director, Market Research

This two-year fellowship offers the opportunity to join a rapidly evolving access organization that is an industry leader in ensuring patient and provider access to therapy. Within the fellowship program, the Fellow will have the opportunity to gain experience working in multiple components of the organization, with an emphasis in Hematology and Oncology. Through four rotational opportunities, the Fellow will build core foundational marketing skills, develop a comprehensive understanding of drug pricing, payer-provider reimbursement, and patient affordability. Additionally, the fellow will gain exposure to many unique experiences and gain valuable insight into tactics and cross-matrix initiatives used to ensure patient access to quality care.

During this program, the fellow will:

- Work within the Patient Access Support Services team, evaluating the evolving healthcare landscape to assess the implications for provider reimbursement and patient affordability
- Create materials, including both traditional and digital content, to communicate the proper billing and coding for infusible products to support launch and label updates
- Understand challenges and business drivers across multiple channels including Payers, Integrated Delivery Networks, Group Purchasing Organizations, and Pathway organizations
- Gain experience in economic modeling to shape pricing strategy for new and existing products based upon shifting marketplace pressures and dynamics
- Contribute to the brand payer strategy by evaluating payer management trends, emerging access influencers, and the evolving competitive landscape
- Interact with medical strategy, health economics and outcomes research, and market research to develop promotional materials communicating the value of our products to managed care organizations.

PRECEPTORS:

- **Greg Long**  
  Executive Director, US Hematology - Oncology Strategic Payer Marketing

- **Alma Howard**  
  Senior Director, Patient Access Support Services

- **Fred Zeleznik**  
  Executive Director, Pricing and Contracting
Policy & Advocacy

This industry leading fellowship provides opportunities to work with seasoned professionals within both US Policy & Government Affairs and US/Global Patient Advocacy. The fellow will gain experience working across a matrix team (commercial, clinical development, medical, HEOR, market access, policy communications and legal) to gather expert patient advocate insights, engage with relevant non-profit organizations, develop advocacy plans that optimize access to high quality medicines for patients and incorporate patient input into the drug development lifecycle continuum. During this time of continued reform and evolution of the U.S. healthcare system, the fellow will develop a deep understanding of how healthcare policies are developed and implemented within the US, and how they impact patients, providers, payers, Bristol Myers Squibb and the biopharmaceutical industry. The fellow will interact and collaborate with stakeholders across Bristol Myers Squibb and gain experience working with patient advocacy organizations, professional organizations, trade associations, policy stakeholders and other organizations that contribute to the policymaking process and the overall changing healthcare landscape.

U.S. POLICY & GOVERNMENT AFFAIRS

• Evaluate U.S. healthcare policy proposals and develop related analyses to help support policy position development for the federal and state government affairs teams across multiple therapeutic areas

• Support Bristol Myers Squibb participation in pharmaceutical industry trade associations and other stakeholder efforts on priority public policy issues, including those that affect patient access to innovative medicines

• Develop an understanding of how public policy issues impact the biopharmaceutical industry, patients, caregivers, providers, and the overall healthcare delivery system

PATIENT ADVOCACY

• Develop, execute, and monitor strategic national, continental, regional, and global advocacy plans that center on
  o Optimizing patient access and care while educating new and existing partners on the value of our medicines.
  o Educating the advocacy community about the science behind our medicines while seeking their input and collaboration
  o Providing internal leadership to inform company positions, vision and execution
  o Generating overarching, cross-disease insights with a focus on expanding our impact through patient advocacy and a commitment to health equity

• Collaborate across matrix teams (commercial, clinical development, medical, HEOR, market access, policy communications and legal) to develop and execute advocacy initiatives

PRECEPTORS:

• **Brian Lee, PharmD**  
  Director, Patient Advocacy

• **Lisa Nelson**  
  Executive Director, U.S. Policy & Federal Government

Shailee Gusani, PharmD  
Second-Year Fellow  
Rutgers University  
Ernest Mario School of Pharmacy
NEW:
Worldwide Commercial Development: Oncology

This newly created, two-year commercial fellowship provides a unique opportunity to contribute to the advancement of the BMS Oncology early stage pipeline and to assess business development opportunities for strategic partnerships and licensing. This is a highly visible and strategically important area for the company as we approach loss of exclusivity for key products over the course of the next 5-10 years. The fellow will be a member of the worldwide oncology commercial team and will partner with the matrix to evaluate the potential impact of internal and external innovation for patients. The individual selected for this fellowship will have the opportunity to leverage their clinical background as they continue to learn about cutting edge science and assess commercial potential of future products.

During this program, the fellow will:

• Prioritize business opportunities and develop target opportunity profiles to guide development decisions
• Provide commercial input into potential development paths for assets based on unmet need, competitive intensity, and size of opportunity
• Understand customer needs as well as drivers and barriers to product adoption
• Collaborate with key matrix team members to deliver robust assessments that include a comprehensive review of the external competitive environment, external insights gathered from market research and TL discussions, market access considerations and revenue projections
• Develop business cases for presentation to senior management
• Participate in the evaluation of external opportunities based on strategic fit, strength of science, and financial attractiveness
• Partner with business development and cross functional teams to identify new opportunities consistent with Oncology Strategy

PRECEPTORS:

• John Calhoun, PhD
  Executive Director, Worldwide Oncology Commercial - Early Assets

• Jessica Cairns, PharmD
  Executive Director, Worldwide Oncology Commercial, Business Development and Clinical Collaborations
2022

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM

Summit East (SME)
Summit, NJ
The two-year Medical Affairs Fellowship is designed to provide broad exposure and opportunities to understand the various roles within the Hematology Medical Affairs organization. Throughout the fellowship, the fellow will further develop their knowledge base within the hematology space by acquiring disease state knowledge and mastering clinical data involving the Bristol Myers Squibb product portfolio and competitor data. The fellow will learn various aspects of clinical research (company sponsored trials, investigator-initiated trials, cooperative group trials, and registries) while working collaboratively with medical disease teams and cross-functional partners.

Hematology Medical Affairs Fellowship Objectives:

• Gain a broad knowledge and understanding of assigned disease areas including, but not limited to: disease biology, currently available therapeutic options, agents in development, and unmet medical needs for specific patient segments.

• Gain product-related expertise in each assigned disease area and engage in scientific and strategic discussions with key internal and external stakeholders.

• Participate in the clinical data review of study data, development, monitoring and close-out of ongoing clinical research trials and activities on respective disease teams, including company sponsored research studies and registries (based upon the life-cycle of projects).

• Contribute to the evaluation of investigator-initiated trial concepts and how each concept strategically relates to open research questions that have been prioritized within the department and disease team.

• Support the medical disease teams with content preparation and planning for medical congresses (e.g. ASCO, ASH) and other key external meetings, including advisory boards, scientific steering committee meetings, and clinical study data monitoring meetings.

• Refine presentation and verbal communication skills by developing and presenting material at various meetings involving internal and competitor data and key medical updates.

• Collaborate with cross functional team members, including Medical Science Liaisons (MSLs), Scientific Communications, Scientific Education, Medical Information, and Learning & Development teams, to create and execute on medical tactical plans.

PRECEPTORS:

• Irene Sheng DeGutis PharmD, RPh
  Senior Director, U.S. Medical Affairs

• Adeola Makinde, PhD
  Senior Manager, US Medical Affairs
This 2-year Fellowship will prepare talented individuals with strong interests in pursuing a Health Economics and Outcomes Research (HEOR) career in the biopharmaceutical industry. As the US healthcare system evolves to focus on improving outcomes while reducing costs, healthcare payers and decision makers are keen on understanding the value of medicines. HEOR data is uniquely positioned to demonstrate value and guide decision making. The US HEOR team is responsible for developing, executing, and communicating studies that help define the real-world value of BMS products. In addition, HEOR professionals generate scientific evidence to meet unmet medical needs and ensure access to these innovative products. The fellow will work alongside experienced preceptors to conduct research studies and communicate the value of BMS medicines to various healthcare stakeholders such as payers, providers, and patients. Additionally, the fellow will serve as an essential part of a well-integrated matrix team and will collaborate with a variety of internal partners from both US and worldwide teams (i.e., medical affairs, payer marketing, commercial, policy & advocacy, clinical development, regulatory, etc.). During this program, the fellow will:

• Build a foundational understanding of HEOR methods and practices through designing and executing studies that examine clinical, economic, and humanistic outcomes
• Gain diverse experiences through working with products at various points of their life cycle
• Lead and contribute to the generation of HEOR evidence that will be used to demonstrate the value of BMS medicines to internal and external stakeholders
• Communicate scientific evidence and the value of BMS medicines through publications and external presentations at national conferences
• Think strategically and collaborate with matrix teams to build comprehensive value propositions to improve market access and patient outcomes
• Learn how HEOR contributes to and is impacted by healthcare quality, performance measures, and the health policy environment in the US

**PRECEPTOR:**

• Kyna Gooden, PhD
  Executive Director, WW HEOR – US Markets, Hematology
Non-Recruiting Fellowships

WORLDWIDE VALUE, ACCESS, AND PRICING
Raj Shah, PharmD
Rutgers University
Ernest Mario School of Pharmacy

WORLDWIDE CARDIOVASCULAR MEDICAL STRATEGY
Emily Liu, PharmD
University of Pittsburgh
School of Pharmacy

US IMMUNOLOGY FIELD MEDICAL OPERATIONS/MSL
Ankush Sahani, PharmD
St. John’s University
College of Pharmacy and Health Sciences

CELL THERAPY FRANCHISE
Jake Kinley, PharmD, MBA
University at Buffalo

US ONCOLOGY PORTFOLIO MARKETING
Jasmin Zarrin, PharmD
Rutgers University
Ernest Mario School of Pharmacy
The Bristol Myers Squibb Fellowship program has provided me with a solid foundation that prepared me for a successful career in the pharmaceutical industry. As a Fellow, I was an integral part of my team and was provided with a breadth of experiences. My preceptors and mentors were truly invested in my career growth and development. The experiences and friendships I have gained throughout my Fellowship and current role are invaluable and will last me a lifetime. The program provides you with the necessary tools and opportunities you need to lead you on a path towards a rewarding career. I am proud to be a part of an organization that has a commitment and passion for patients.

Bristol Myers Squibb is a great company for pharmacists who are wanting to enter the pharmaceutical industry. The company recognizes the value of the unique skill set, training, and experience that enables pharmacists to excel and rise to important management and leadership roles. The diversity and cohesiveness of our PharmD program, and our associated pharmacy community at Bristol Myers Squibb, provides an exceptional experience of seeing, doing, and teaching, which readily prepares our Fellows/Residents to become future leaders within both our Medical and Commercial organizations. As leaders at Bristol Myers Squibb, we appreciate the importance of attracting and retaining these talented individuals to fulfill the Bristol Myers Squibb Company mission of helping patients prevail over serious diseases. The program provides you with the necessary tools and opportunities you need to lead you on a path towards a rewarding career. I am proud to be a part of an organization that has a commitment and passion for patients.

Selecting a fellowship at BMS was one of the best decisions I made to jump start my career during the fellowship interview and selection process. As a company with both a people and patient centric culture, a career at BMS for me has meant some of my proudest moments have had an impact for both patients and my career. Nearly a decade later, I look back on my time and think about the people both in the fellowship community and beyond who have helped me succeed and contributed to my professional development. I can recommend no better place to both start and grow your career.
Bristol Myers Squibb Fellowship Alumni

Medical Affairs
Alex Brun Group Director, Medical Education
Amanda Scofield Director, Relatlimab Melanoma
Anthony Salvatore Medical Scientist, US Medical Oncology, Relatlimab
Boas Park Associate Medical Scientist, US Medical Oncology, Melanoma
Brandon Elpers Associate Director, Fibrosis WW Medical
Brielle Carramusa Associate Director, Franchise Medical Services
Catherine Merrill Director, Early Transition Assets/Rela WW Scientific Publications
Dorothy Zissler Senior Manager, Zaposia WW Scientific Publications
Imani Pelt Senior Manager, Scientific Publications Oncology
Irene Degulis Director, US Medical Affairs Hematology, Myeloid Data Strategy Lead
Iwona Golczewska Director, Oncology, Solid Tumor WW Scientific Content & US Market Capabilities
Jagrutti Amin Associate Director, US Medical Promotional Review, Oncology
Joseph Kostal Senior Manager, Franchise Medical Services
Jully Kim Senior Director, Medical Promotional Review
Kaleen Barbary Director, Hematology/Cell Therapy, WW Scientific Content & US Market Capabilities
Keith Wittstock Senior Manager, Immunoscience Medical
Kim Tran Executive Director, US Field Medical Hematology
Kiri Roland Senior Manager, US Medical Promotional Review, Scientist
Laura Williams Medical Scientist, US Medical Oncology, Pan Tumor
Lynn Anyasiee Associate Director, Medical Education – Immunology
Melissa Harris Senior Vice President, Early Development Program Leadership
Mina Awad Medical Science Liaison, CAR T
Monica Anis Associate Director, Research & Early Development Alliances
Nabomita Thomas Director Medical, US Medical Oncology, Pan Tumor
Jessie Hwang Associate Director, TK2i Medical Scientist
Patrick Liu Associate Director, Franchise Medical Scientist
Pavith Sing Clinical Trial Lead, Lung Cancer
Pooja Gupta Associate Director, WW Medical, Adjuvant EC/GEJC HCC
Priya Darouian Director, Medical Capabilities
Samantha Gotheil Vice President, US Medical Oncology
Samantha Pomponi Associate Medical Director, Rheumatology-Deucravacitab
Sandhya Balachandar Associate Director, Relatlimab HCC
Sonie Lama TK2i Medical Scientist
Srufi Goddam Associate Director, Melanoma Worldwide Scientific Publications
Swara Kasbekar Senior Manager, US Medical Promotional Review, Scientist
Thomas Lehman Director, TK2i Rheumatology Worldwide Medical
Krishnan Viswanadhan Senior Vice President, Global Cell Therapy Franchise Lead
Max Prokoppovich Medical Scientist, US Medical – Oncology
Teena John Senior Manager, Fibrosis WW Medical
Vincent Tran Senior Manager, WW Scientific Content and US Market Capabilities Hematology
Josh Linton Senior Manager, Medical Scientist, US Medical Oncology, Relatlimab
Annie Liu Senior Manager, Franchise Medical Services
Johnathan Kloss Senior Manager, Franchise Medical Services
Ijeoma Nwosu Associate Director, Medical Scientist, US Medical Oncology GI
Jamie Bunn Associate Director, CRC WW Scientific Publications

Field Medical
Bryandt Douglas Medical Science Liaison, Hematology
Bryce Adams Senior Medical Science Liaison, Melanoma, JG/L/GI
Carmelo Alonso Field Medical and Communications Specialist, Cardiovascular
Carol Davis-Shiloh Head, US Field Medical Oncology
Daniel Boulos Field Medical Communication Specialist
Daniel Dilanj5 Medical Science Liaison, Neurology Southern California
Justin Balint Health Systems Liaison
Katherine Sprague Executive Medical Science Liaison, Cardiovascular
Khushbu S Shah Field Medical Communication Specialist Oncology
Lauren Clouse Senior, Medical Science Liaison, Dermatology
Shannon Chandy Associate Director, EICC WW Scientific Publications
Will Jackson Senior Medical Science Liaison, Lung, H&EIN, Glioblastoma, Breast Cancers
Zack Inge Medical Science Liaison, Cardiovascular
Jordan D Geissinger US Field Medical Communication Specialist, Oncology
Aaron North Medical Science Liaison, Gastroenterology

BMS Foundation (Corporate Philanthropy)
Priscilla Ko Director, BMS Foundation

Commercial

Alex Sharer Senior Manager, Value Generation
Ashwini Deshpande General Manager, India
Bernard Lee Director, Melanoid, US Hematology, Forecasting, BIA – Enterprise Strategy & Performance
Carissa Drannbauer Business Unit Director, Switzerland
Chloe Stacy Oncology Associate Manager Field Operations, Oncology
Christine Ghoebriel Director, WW Access Strategy Lead, Melanoma
Dylan Atkinson Associate Director, Payor Marketing, NSCLC
Jennifer Liu Cardiovascular Retail Territory Business Manager
Jennifer Mannino Senior Territory Business Manager, Oncology
Karishma Patel Senior Manager, Customer & Market Insights, Cardiovascular
Landon Shupe Senior Manager, Worldwide Value Access & Pricing, Hematology
Leo Rudowsky Associate Director, Melanoma Strategic Payor Marketing
Peter Fent Associate Director, Customer & Market Insights, Hematology/CAR T
Venkatesh Satram Senior Manager, WW Hematology, Myeloid, CC486
Lindsey McKeown Associate Director, WW Oncology, Commercial Strategy
Evelyn Abramson Product Manager, Oncology, Network Marketing
Lindsay Adair Senior Manager, Strategic Payer Marketing, Oncology, Solid Tumors
Hannah Gardocki Senior Manager, US Product Marketing, Abecma
Nina Johnson Senior Manager, US Oncology Portfolio Marketing Congress Lead
Jade Hoang Associate Director, US Deucravacitab HCP Marketing

Regulatory Affairs
Amandeep Riar Manager, Regulatory Affairs
Ashley Pereira Executive Director, Oncology Team Leader
Robert Kalesnik-Orszulak Director, Global Regulatory Strategy and Policy, Oncology
Sagar Shah Director, Innovation Lead, Global Regulatory Strategy Science and Policy
Sekayi Mushonga Executive Director, GRSP, Immunology, Neuroscience, and Fibrosis
Christine Alonso Director, US Commercial Regulatory Affairs, Oncology
Divisha Dixit Associate Director, US Commercial Regulatory Affairs
Elsa Pan Director, CV/Immunology/Fibrosis
Frances Sounios Senior Manager, Scientific Engagement, Oncology
Yen Krystal Miao Associate Director, US Commercial Regulatory Affairs
Alexander Cheung Manager Commercial Regulatory Affairs
Becca Shin Senior Manager, Oncology, Global Regulatory Strategy and Policy
Omar Nurillo Senior Manager, Commercial Regulatory Affairs
Matthew Lupo Director, US Commercial Regulatory Affairs
Yen Krystal Maio Associate Director, US Commercial Regulatory Affairs

Clinical
Alex Azrilevich Senior Director, Early Development Program Lead
Alex Genestksy Director Search and Evaluation, Hematology
Amy Kim Manager Clinical Scientist, Late Clinical/ Global Drug Development
Joseph Pariseau Associate Director, Strategic Integrated Evidence Lead, Myeloid
Kendall Sullivan Clinical Scientist
Marina Youssouf Senior Clinical Scientist
Nicholas Favatella Senior Clinical Scientist
Corey Rittings Clinical Development Team Lead
Trixia Camacho Clinical Development Lead, P&O
Victoria Berger Clinical Scientist
Sean Ahern Clinical Scientist, Cell Therapy
Brenda Yuan Associate Clinical Scientist
Richie Ube Associate Clinical Scientist, Cell Therapy

Business Development
Mary Moore Senior Director, Performance Analytics & Reporting
Matt Bunn Senior Director, TM Transactions
Enoch Yue Senior Manager, Business Development, Oncology Search & Evaluation

HEOR
Alexander Marshall Worldwide Value and Access
Brian Ung Associate Director, US Field HEOR National Accounts
Prianka Singh Worldwide HEOR Oncology Lead
Toya Poreto Senior Manager, US HEOR Oncology
Thushara Koratthil Worldwide HEOR Publications Lead
Micah Anthony Senior Manager, WW HEOR Publications

Policy
Aakash Patel Manager, Policy Research
Kemi Ousdina Associate Director, Patient Advocacy and Professional Relations
Stefanie Wiegand Director, Proactive Initiatives
Adeumbo Odunlami Medical Scientist, Global Health Equity Platform
ALUMNI

From Other Partner Companies

**Medical**
- Dalal Nesheiwat (Novartis) Executive Director, Medical Data Generation and Strategic Collaborations
- John Vaile (Bayer) Senior Director, WW Medical Immunology & Fibrosis
- Julie Jeanes (TKL Research) Senior Director, US Medical Oncology
- Kristo Hudak (TKL Research) Associate Director, WW Scientific Publications
- Marta Molina (Bimark) Senior Director, Oncology WW Scientific Publications
- Ralu Vlad (Roche) Vice President, Development Program Lead, PD&D
- Sapna Patel (Novo Nordisk) Senior Manager, GU WW Scientific Publications
- Shalon Jones (Promius Pharma) Associate Director, Global Medical Affairs, Myeloid
- Unicef-Ann Flores (Pfizer) Specialist, WW Field Medical Communications
- Basirat Adeyemi (Merck), Global Medical Affairs, Myeloid Leuke
- Christopher Russo (Pfizer), Associate Director, Cendakimab WW Medical

**Business Development**
- Bryan Campbell (Novartis) Vice President, WW Oncology, Early Assets, Business Development & Bio-Markers
- Jessica Cairns (Roche) Executive Director, WW Oncology Commercial, Business Development and Clinical Collaborations

**Regulatory Affairs**
- Andro Shenouda (Merck) Associate Director, Global Regulatory Strategy Lead
- Charles Frost (Roche) Senior Director GSRD, Early Development
- Jennifer Dudinak (Roche) Head of Global Regulatory Sciences, Strategy and Policy
- Matthew Lamb (UNC) Head, Immunology, Fibrosis & Neuroscience TA Strategy
- Matthew Wong (Daiichi-Sankyo) Director, Global Regulatory Strategy, Hematology
- Narin Ahmed (Novartis) Senior Director, Regulatory Affairs
- Rubin Modi (Novartis) Associate Director, Regulatory Strategy Hematology
- Vrunda Patel (Bayer) Associate Director, Global Regulatory Strategy and Policy
- Jateh Major (Merck) Associate Director, Regulatory Affairs Oncology
- Kenneth Hu (Sanofi) Global Regulatory Manager
- Lincy George (Novartis) – Executive Director, Oncology Regulatory Affairs

**Commercial Regulatory Affairs**
- Akshay Patel (Novartis) Manager, US Commercial Regulatory Affairs
- Jeff Sniggs (Acorda) Senior Manager, US Commercial Regulatory Affairs
- Bridget McGugan (Daiichi-Sankyo) Senior Manager, Global Regulatory Affairs

**Clinical**
- Angela Tang (Roche) Associate Director, Documentation Lead
- Duong Nguyen (Roche) Associate Director, Operations Portfolio Lead
- Jennifer Poon (Merck) Clinical Scientat Team Lead, CC-92480/POW/REV
- Jenny Wong (Roche) Senior Director, Global Feasibility Solid Tumor
- Jessica Garzon (Roche) Senior Clinical Research Scientist
- Joseph Fiore (Merck) Clinical Development Lead, Oncology
- Michelle Hudson (Novartis) Senior Director, Head of Clinical Center of Excellence
- Ronak Patel (Pfizer) Associate Director, Drug Development Project Manager
- Vi Nguyen (Novartis) Clinical Scientific Team Lead, Iberdomide
- Jesse Siegel (Merck) Senior Clinical Scientist, Late Development Global Drug Development
- Julia Spiridigliozzi (Merck) Clinical Scientist
- Kinjal Kashyap (Bayer) Associate Director, Global Risk Management
- Sunee Degaonkar (Merck) Clinical Scientist, Oncology Clinical Development
- Noamay Sarkis (Novartis) Clinical Scientist, Oncology Clinical Development

**Policy**
- Brian Lee (Sanofi) Director, Policy and Advocacy
Application Process and Eligibility Requirements:

Pharmacy Fellows for the Rutgers Pharmaceutical Industry Fellowship Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy degree from an ACPE-accredited institution before July 1 of the fellowship term.

How to Apply:

Interviewing is conducted on a rolling basis. Interested candidates may submit their application and supporting materials (letter of intent, curriculum vitae, and three letters of recommendation) during October 2021 by visiting our website at: pharmafellows.rutgers.edu

All application materials must be submitted electronically to the RPIF Website.

<table>
<thead>
<tr>
<th>REQUIRED ITEMS</th>
<th>DEADLINE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>LETTER OF INTENT (LOI)</td>
<td>NOVEMBER 1ST</td>
</tr>
<tr>
<td>CURRICULUM VITAE (CV)</td>
<td>NOVEMBER 1ST</td>
</tr>
<tr>
<td>3 LETTERS OF RECOMMENDATION (LORs)</td>
<td>DECEMBER 5TH</td>
</tr>
</tbody>
</table>

*Candidates are considered on a rolling basis. Submission of materials prior to deadline is strongly encouraged.

Your Letter of Intent & Letters of Recommendation should be addressed to:
Joseph A. Barone, Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020